NCT04020523

Brief Summary

Evaluation of advanced MRI acquisition techniques (perfusion and diffusion) to detect breast cancer. Two MR advanced sequences will be added to a standard breast MRI protocol for evaluation purpose.

Trial Health

15
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jul 2019

Longer than P75 for not_applicable breast-cancer

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 24, 2019

Completed
1 month until next milestone

Study Start

First participant enrolled

July 1, 2019

Completed
15 days until next milestone

First Posted

Study publicly available on registry

July 16, 2019

Completed
3.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2022

Completed
1.7 years until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2024

Completed
Last Updated

October 20, 2021

Status Verified

October 1, 2021

Enrollment Period

3.3 years

First QC Date

May 24, 2019

Last Update Submit

October 15, 2021

Conditions

Keywords

MRIbreastcancerscreeninginnovative sequences

Outcome Measures

Primary Outcomes (2)

  • Mammary lesions Visualization on ultrafast injected dynamic MRI: Yes/No

    to evaluate whether ultrafast injected dynamic breast MRI, coupled or not with a diffusion sequence, allows to improve the specificity of standard MRI while maintaining the same sensitivity

    Day 1 at inclusion

  • Mammary lesions Visualization with a diffusion sequence

    to evaluate whether ultrafast injected dynamic breast MRI, coupled or not with a diffusion sequence, allows to improve the specificity of standard MRI while maintaining the same sensitivity

    Day 1 at inclusion

Secondary Outcomes (7)

  • Quantitative perfusion parameters : Enhancement Integral (EI (%))

    Day 1 at inclusion

  • Quantitative perfusion parameters : Maximum Slope of Increase (MSI (%/sec))

    Day 1 at inclusion

  • Quantitative perfusion parameters : Maximum of enhancement (Rmax (%))

    Day 1 at inclusion

  • Quantitative perfusion parameters : Timing of Maximum of enhancement (RmaxTiming (sec))

    Day 1 at inclusion

  • Quantitative perfusion parameters : Wash-inrate (WIR (%/sec)

    Day 1 at inclusion

  • +2 more secondary outcomes

Study Arms (1)

Patient with an injected breast MR exam

EXPERIMENTAL
Other: MRI sequence

Interventions

The MR sequences added to the protocol are dedicated sequences for perfusion and diffusion imaging of breast lesion.

Patient with an injected breast MR exam

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult patient
  • Patient who has signed a consent form to participate in the study
  • Affiliated patient or beneficiary of a social security scheme
  • Patient with an injected breast MR exam planned as part of her care pathway.

You may not qualify if:

  • Patients under guardianship or curatorship
  • Pregnant or breastfeeding patients
  • Patients with contraindications to realization of an MR exam and an injected MR exam

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Breast NeoplasmsNeoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

  • Isabelle THOMASSIN-NAGGARA, PU-PH

    Assistance Publique - Hôpitaux de Paris

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 24, 2019

First Posted

July 16, 2019

Study Start

July 1, 2019

Primary Completion

November 1, 2022

Study Completion

July 1, 2024

Last Updated

October 20, 2021

Record last verified: 2021-10